EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Validation of transcriptome signature reversion for drug repurposing in oncology

Karel K M Koudijs iD, Stefan Böhringer, Henk-Jan Guchelaar

Briefings in Bioinformatics · 19.01.2023 · 24 (1)

DOI: 10.1093/bib/bbac490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Briefings in Bioinformatics, online erschienen am 29.11.2022. Verfasst von Karel K M Koudijs und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center (LUMC); 2333 ZA Leiden, The Netherlands. Hauptthemen laut MEDLINE: Transcriptome, Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transcriptome signature reversion (TSR) has been extensively proposed and used to discover new indications for existing drugs (i.e. drug repositioning, drug repurposing) for various cancer types. TSR relies on the assumption that a drug that can revert gene expression changes induced by a disease back to original, i.e. healthy, levels is likely to be therapeutically active in treating the disease. Here, we aimed to validate the concept of TSR using the PRISM repurposing data set, which is—as of writing—the largest pharmacogenomic data set. The predictive utility of the TSR approach as it has currently been used appears to be much lower than previously reported and is completely nullified after the drug gene expression signatures are adjusted for the general anti-proliferative downstream effects of drug-induced decreased cell viability. Therefore, TSR mainly relies on generic anti-proliferative drug effects rather than on targeting cancer pathways specifically upregulated in tumor types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TranscriptomeNeoplasmsHumansDrug RepositioningGene Expression ProfilingMedical Oncology

Stichwörter der Autor:innen

BioinformaticsDrug repositioningGene expressionOncologySystematic validation

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center (LUMC); 2333 ZA Leiden, The Netherlands.
  • Department of Biomedical Data Sciences, Leiden University Medical Center (LUMC); 2333 ZA Leiden, The Netherlands.

ORCID-Profile: Karel K M Koudijs

Zitieren

APA

Koudijs, K. K. M., Böhringer, S., & Guchelaar, H. J. (2023). Validation of transcriptome signature reversion for drug repurposing in oncology. Briefings in Bioinformatics, 24(1). https://doi.org/10.1093/bib/bbac490

Vancouver

Koudijs KKM, Böhringer S, Guchelaar HJ. Validation of transcriptome signature reversion for drug repurposing in oncology. Briefings in Bioinformatics. 2023;24(1). doi:10.1093/bib/bbac490

BibTeX
@article{Koudijs2023,
  author = {Koudijs, Karel K M and Böhringer, Stefan and Guchelaar, Henk-Jan},
  title = {Validation of transcriptome signature reversion for drug repurposing in oncology},
  journal = {Briefings in Bioinformatics},
  year = {2023},
  volume = {24},
  number = {1},
  doi = {10.1093/bib/bbac490}
}
Kostenlos starten →